![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Integrated Analysis of Emergent Drug Resistance Through 48 Weeks from Clinical Studies of HIV-1 Treatment-Naive Subjects Receiving E/C/F/TAF
|
|
|
Reported by Jules Levin
EACS 2015 Oct 21-25 Barcelona, Spain
MD Miller, N Margot, KM Kitrinos, M Fordyce, S McCallister, and C Callebaut
Gilead Sciences, Inc., Foster City, CA, USA
![EACS1.gif](../images/110215/110215-4/EACS1.gif)
![EACS2.gif](../images/110215/110215-4/EACS2.gif)
![EACS3.gif](../images/110215/110215-4/EACS3.gif)
![EACS4.gif](../images/110215/110215-4/EACS4.gif)
![EACS5.gif](../images/110215/110215-4/EACS5.gif)
![EACS6.gif](../images/110215/110215-4/EACS6.gif)
![EACS7.gif](../images/110215/110215-4/EACS7.gif)
![EACS8.gif](../images/110215/110215-4/EACS8.gif)
![EACS9.gif](../images/110215/110215-4/EACS9.gif)
![EACS10.gif](../images/110215/110215-4/EACS10.gif)
![EACS11.gif](../images/110215/110215-4/EACS11.gif)
![EACS12.gif](../images/110215/110215-4/EACS12.gif)
![EACS13.gif](../images/110215/110215-4/EACS13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|